Gilead Purchases FDA Priority Review Voucher For $125M

NPR: Gilead Buys Shortcut For FDA Drug Review For $125 Million
“…In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company’s choice from Knight Therapeutics, a Canadian company. The priority review voucher entitles Gilead to move a drug of its choice through the FDA four months faster than the normal track. … The legal shortcut was created in 2007 as a reward for companies developing drugs for specific neglected tropical diseases…” (Hensley, 11/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.